
DT-120 in Anxiety and Depression: Phase 3 Efficacy and Safety Findings
Learn more about DT-120 to treat GAD and MDD.
DT-120, a pharmaceutically optimized formulation of lysergide, was delivered as an orally disintegrating tablet that dissolved fully within seconds, according to Dan Karlin, MD, MA. The formulation reduced the time to efficacious exposure to about 30 minutes from about 1 hour with the earlier powder-in-capsule formulation, making more of each clinic session active treatment time.
Topline data were reported from 3 phase 3 studies: Voyage and Panorama in generalized anxiety disorder (GAD) and Emerge in major depressive disorder (MDD). A 4th phase 3 study in MDD, Ascend, was ongoing. Voyage (214 participants) compared DT-120 100 µg with placebo, while Panorama (245 participants) randomized participants 2:1:2 and added a 50-µg arm. Both GAD studies included a 12-week double-blind part A and a 40-week extension with up to 4 additional open-label treatments. Participants entered with a baseline Hamilton Anxiety Rating Scale score of about 28. At week 12 after a single dose, the placebo-adjusted improvement with 100 µg was 5.4 points in Voyage and 5.1 points in Panorama.1,2
Adverse events were almost entirely confined to the day of dosing and were consistent with the known pharmacology of the drug. Most were mild to moderate in severity. No drug-related serious adverse events occurred, and the development program showed no suicidal or self-injury signal and no increased suicide-related risk.²
Response was consistent across both indications. “The observed response is pretty consistent across the population and we can’t identify any a priori features of a patient that would indicate that the drug would be more or less effective in them,” Karlin said. Length of illness and prior treatment history did not change this pattern.
Definium planned to file a new drug application in the first half of 2027 and was pursuing broad labels in GAD and MDD, with the filing strategy under discussion with the US Food and Drug Administration. No new drug had been approved for GAD in just under 20 years. For patients in whom the drug was efficacious, Karlin described a potential shift in practice: “It’s a whole new paradigm, a whole new way of thinking about treatment, a new way of thinking about what our goals of treatment could be.”
Dr Karlin is the chief medical officer of Definium Therapeutics.
References
1. Duerr HA. DT120 (lysergide) shows rapid, lasting relief for generalized anxiety in phase 3 trial. Psychiatric Times. August 12, 2026.
2. Definium Therapeutics announces positive topline results from phase 3 Panorama study of DT120 ODT in generalized anxiety disorder. Press release. Published September 14, 2026. Accessed November 16, 2026.
Related to this article








